A Study of Trastuzumab Deruxtecan DS-8201a in Children, Adolescents, and Young Adults with Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Led by National Cancer Institute (NCI) · Updated on 2026-10-28
55
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating trastuzumab deruxtecan DS-8201a, an antibody-drug conjugate, for treating patients with osteosarcoma, Wilms tumor WT, or desmoplastic small round cell tumor DSRCT that is newly diagnosed, recurrent, or refractory to previous treatments. This phase III trial aims to estimate the maximum tolerated dose and antitumor activity of DS-8201a, focusing on children and young adults with these cancers. The study also explores safety, pharmacokinetics, and potential biomarkers predicting response.
Participants receive trastuzumab deruxtecan intravenously over 30 to 90 minutes on day 1, repeated every 21 days for up to 35 cycles unless disease progresses or unacceptable toxicity occurs. Throughout the study, patients undergo imaging tests such as CT and MRI, heart function assessments via echocardiography or MUGA scans, and blood sample collections. After completing treatment, there is a follow-up visit six months later.
During the trial, researchers monitor adverse events, tumor response, progression, and survival outcomes. Blood tests and imaging help assess treatment effects and safety. The primary outcome includes determining the dose tolerated by children aged 2 to less than 12 years. Secondary outcomes cover safety and response rates up to one year. Participants are observed closely with scheduled assessments to support these measurements over the study period.
CONDITIONS
Brief Title
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Investigational: DS‑8201a
Context: Standard multimodal care
What it is
An investigational antibody‑drug conjugate of trastuzumab linked to deruxtecan given intravenously to treat recurrent or refractory pediatric solid tumors.
A combination of chemotherapy often with surgery and/or radiation as the usual approach for recurrent or refractory tumors in children and young adults.
Role in the trial
Administered investigational therapy in a single‑arm treatment setting.
Not studied within this trial; represents the comparator in real‑world care.
Primary use
To estimate maximum tolerated dose, recommended phase 2 dose, safety profile, and antitumor activity in recurrent or refractory Wilms tumor or DSRCT (Phase 1/2)
Aimed at disease control in recurrent/refractory pediatric solid tumors using chemotherapy plus local treatments.
How it is given or performed
Given intravenously as trastuzumab deruxtecan antibody‑drug conjugate.
Delivered as multimodal therapy: systemic chemotherapy plus surgery or radiation as appropriate.
Evidence status
Evidence limited to early‑phase trial; antitumor activity under evaluation.
Recognized real‑world approach based on historical multimodal management.
Important risks
Safety profile under evaluation; adverse events being monitored in trial.
Standard treatments are associated with known risks from chemotherapy, surgery, or radiation.
Important limitations
Single‑arm early‑phase study without control arm limits ability to assess comparative benefit or long‑term outcomes.
Lack of current trial data on efficacy in this specific recurrent/refractory setting in registry.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 12Years - 39Years
All Genders
Eligibility Criteria
You may qualify if you...
Patients aged 2 to less than 12 years for Phase 1; Wilms tumor patients less than 18 years; DSRCT patients aged 12 to 39 years before Phase 1 completion
Diagnosis of Wilms tumor or desmoplastic small round cell tumor confirmed by histology
Measurable disease by RECIST 1.1 criteria
Refractory disease or high-risk relapse for Wilms tumor
Relapsed or refractory disease for desmoplastic small round cell tumor
Received standard initial therapy including systemic therapy plus radiation or surgery
ECOG performance status 0 or 1 (Karnofsky or Lansky scores as appropriate)
Recovery from prior anti-cancer therapies meeting specified minimum intervals
No prior HER2-targeted therapies including antibody-drug conjugates or HER2 receptor therapies
At least 14 days since last surgery
Adequate blood counts and organ function within defined limits
Corrected QT interval below 480 ms
Pulse oximetry above 93% on room air
Well-controlled seizure disorder if applicable
HIV patients on effective therapy with undetectable viral load
Signed informed consent and assent as appropriate
You will not qualify if you...
Pregnant or breastfeeding women; must use two effective contraception methods or abstain if of reproductive potential
Non-childbearing females or postmenopausal females not using contraception
Males must not freeze or donate sperm during and after study
Receiving unstable corticosteroid doses or other investigational drugs
Receiving other anti-cancer agents or immunosuppressants such as cyclosporine or tacrolimus
Recent use of chloroquine or hydroxychloroquine within 14 days
Recent live vaccine within 30 days prior to enrollment
Prior solid organ transplantation
Recent significant heart conditions or congenital heart defects
Pleural, pericardial, or ascites effusions requiring drainage
Spinal cord compression or active symptomatic CNS metastases
History of severe hypersensitivity to DS-8201a or related HER2 antibodies
Uncontrolled infections or non-healing surgical sites
Substance abuse or psychological conditions interfering with participation
Pulmonary compromise or prior pneumonectomy
History or presence of interstitial lung disease or pneumonitis
Inability to comply with safety monitoring
Detectable hepatitis B or C viral load
Autoimmune or inflammatory disorders with pulmonary involvement
Active primary immunodeficiency
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to approximately 2 years
Participants receive trastuzumab deruxtecan intravenously every 21 days for up to 35 cycles, unless there is disease progression or unacceptable side effects. Imaging and heart function tests, along with blood samples, are collected during this time.
Every 21 days on day 1
Follow-up
Duration - 6 months
After treatment ends, participants have a follow-up visit six months later to monitor health and outcomes.
1 visit
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluation of 68Ga-Labeled B7-H3 Nanobody for ImmunoPET Imaging in Osteosarcoma Patients
Phase 2 Pilot Study of OMO-103 Given by Weekly IV Infusion for Safety and Anti-Tumor Effects in Patients 12 Years and Older With Advanced High-Grade Osteosarcoma
Phase I Open-Label Study Evaluating Safety and Efficacy of XS-02 Capsules in Advanced Solid Tumors
Evaluating Combination Chemotherapy for Newly Diagnosed Diffuse Anaplastic Wilms Tumors and Relapsed Favorable Histology Wilms Tumors
Study of Adding Gefitinib, Trametinib, Disulfiram, and Sunitinib to Standard Chemotherapy for Treating Osteosarcoma in Patients Aged 6 to 49 Years
Multi-Center Phase II Trial of Selinexor for Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
Study of 3D Printed Models Versus Standard Imaging for Planning Tumor Surgery Involving Bone
Abemaciclib Treatment for Adults With Advanced Bone and Soft Tissue Sarcoma Showing CDK Pathway Changes
Adherence to a Personalized Home Exercise Program After Lower Limb Surgery for Bone Tumors in Patients Aged 12 to 90
Haploidentical Stem Cell Transplantation Depleted of TCR and CD19 Cells with Zoledronate for Pediatric Relapsed or Refractory Blood Cancers and High-Risk Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.
Damon R Reed, Katherine A Janeway, Charles G Minard...